Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparin + protamine is a combination of two drugs used in clinical settings where rapid reversal of anticoagulation is required. Heparin is an anticoagulant that works by potentiating the activity of antithrombin-III, thereby inhibiting thrombin and factor Xa, which prevents blood clot formation. Protamine is a strongly basic protein that acts as a specific antagonist to heparin; it binds to the acidic heparin molecule, forming a stable inactive complex and neutralizing its anticoagulant effect. This combination is primarily used during or after procedures such as cardiac surgery or dialysis when it becomes necessary to quickly reverse the effects of heparin to prevent excessive bleeding[1][2][3][5]. The administration of protamine following heparin allows for controlled management of coagulation status in patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin + protamine.